	Application No.	No. Applicant(s)	
Notice of Allowability	09/753,143	ELLIS ET AL.	
	Examiner	Art Unit	
	Kathleen M Kerr	1652	
The MAILING DATE of this communication appear All claims being allowable, PROSECUTION ON THE MERITS IS herewith (or previously mailed), a Notice of Allowance (PTOL-85) NOTICE OF ALLOWABILITY IS NOT A GRANT OF PATENT RI	(OR REMAINS) CLOSED in or other appropriate commeters. This application is	in this application. If not include nunication will be mailed in due o	d course. <b>THIS</b>
1. This communication is responsive to <u>5/28/04</u> .			
2. The allowed claim(s) is/are <u>12,14-17,19,20 and 86-93</u> .			
3.   The drawings filed on are accepted by the Examine	r.		
<ul> <li>4. ☐ Acknowledgment is made of a claim for foreign priority unalled All b) ☐ Some* c) ☐ None of the: <ol> <li>1. ☐ Certified copies of the priority documents have</li> <li>2. ☐ Certified copies of the priority documents have</li> <li>3. ☐ Copies of the certified copies of the priority documents have International Bureau (PCT Rule 17.2(a)).</li> </ol> </li> <li>* Certified copies not received:</li> </ul> Applicant has THREE MONTHS FROM THE "MAILING DATE"	been received. been received in Applicati cuments have been receive	on No ed in this national stage applicat	
noted below. Failure to timely comply will result in ABANDONM THIS THREE-MONTH PERIOD IS NOT EXTENDABLE.		,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,	
5. A SUBSTITUTE OATH OR DECLARATION must be subm INFORMAL PATENT APPLICATION (PTO-152) which give			OTICE OF
6. CORRECTED DRAWINGS ( as "replacement sheets") mus  (a) including changes required by the Notice of Draftspers  1) hereto or 2) to Paper No./Mail Date  (b) including changes required by the attached Examiner's Paper No./Mail Date  Paper No./Mail Date  Identifying indicia such as the application number (see 37 CFR 1 each sheet. Replacement sheet(s) should be labeled as such in the state of the sheet.	con's Patent Drawing Revie s Amendment / Comment c .84(c)) should be written on	or in the Office action of the drawings in the front (not the	back) of
7. DEPOSIT OF and/or INFORMATION about the depo attached Examiner's comment regarding REQUIREMENT			ote the
<ul> <li>Attachment(s)</li> <li>1.  Notice of References Cited (PTO-892)</li> <li>2.  Notice of Draftperson's Patent Drawing Review (PTO-948)</li> <li>3.  Information Disclosure Statements (PTO-1449 or PTO/SB/0 Paper No./Mail Date</li></ul>	6. ☑ Interview S Paper No 8), 7. ☑ Examiner's	Informal Patent Application (PTC) Summary (PTO-413),  Mail Date <u>attached</u> S Amendment/Comment  S Statement of Reasons for Allow  Kathleen M Kerr  Primary Examiner  Art Unit: 1652	·

Application/Control Number: 09/753,143

Art Unit: 1652

### **DETAILED ACTION**

## **Application Status**

1. In response to the previous Office action, a non-final rejection (mailed on April 2, 2004), Applicants filed a response and amendment received on May 28, 2004. Said amendment amended Claims 12, 14-16, and 86 and cancelled Claim 11. Thus, Claims 12, 14-17, 19, 20, and 86-93 are pending in the instant Office action and will be examined herein.

## **Priority**

2. As previously noted, the instant application is granted the benefit of priority for the U.S. non-Provisional Application No. 09/175,828 and 08/559,303 filed on October 20, 1998 and November 15, 1995.

## Withdrawn - Objections to the Specification

- 3. Previous objection to the specification for a typographical error is withdrawn by virtue of Applicant's amendment correcting said error.
- 4. Previous objection to the specification for lacking clarity in Table 1 is withdrawn by virtue of Applicant's amendment and the Examiner's clarification in an informal Examiner's amendment authorized by Applicant (see interview summary July 27, 2004).



Application/Control Number: 09/753,143 Page 3

Art Unit: 1652

# Withdrawn - Claim Rejections - 35 U.S.C. § 112

- 5. Previous rejection of Claims 11, 12, 14-17, and 19-20 under 35 U.S.C. § 112, second paragraph, as being indefinite for the term "*BLM* gene" is withdrawn by virtue of Applicant's amendment drawing all claims to Claim 86 wherein the BLM gene is clearly defined.
- 6. Previous rejection to Claims 11, 12, 14-17, 19-20, and 86-93 under 35 U.S.C. § 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention is withdrawn by virtue of Applicant's amendment drawing all claims to Claim 86 wherein the method is limited to a human subject.
- 7. Previous rejection of Claims 11, 12, 14-17, and 19-20 under 35 U.S.C. § 112, first paragraph, written description, is withdrawn by virtue of Applicant's amendment drawing all claims to Claim 86 wherein the BLM gene in the claim is clearly described.
- 8. Previous rejection of Claims 11, 12, 14-17, and 19-20 under 35 U.S.C. § 112, first paragraph, scope of enablement, is wherein the BLM gene is enabled to the full extent of its scope.

#### **EXAMINER'S AMENDMENT**

9. An examiner's amendment to the record appears below. Should the changes and/or additions be unacceptable to applicant, an amendment may be filed as provided by 37 C.F.R. § 1.312. To ensure consideration of such an amendment, it MUST be submitted no later than the payment of the issue fee.

Application/Control Number: 09/753,143

Page 4

Art Unit: 1652

Authorization for this examiner's amendment was given in a telephone interview with Craig Arnold on September 7, 2004.

#### Amendments to the Claims

- 10. Delete claim 86 and substitute therefor:
- ---86. A method for determining whether a human subject is a carrier of a mutated BLM gene comprising:

determining whether said human subject carries a mutated or unmutated BLM gene;

wherein the unmutated BLM gene comprises SEQ ID NO:72 and wherein the mutated BLM gene comprises one or more of:

- i. a deletion of nucleotides 631-633 of SEQ ID NO:72;
- ii. a substitution of A with T at nucleotide 888 of SEQ ID NO:72;
- iii. an insertion of A after nucleotide 1610 of SEQ ID NO:72;
- iv. a substitution of A with G at nucleotide 2089 of SEQ ID NO:72;
- v. a replacement of nucleotides ATCTGA at position 2281-2286 of SEQ ID NO:72 with nucleotides TAGATTC;
- vi. a substitution of T with C at nucleotide 2596 of SEQ ID NO:72; and
- vii. a substitution of G with C at nucleotide 3238 of SEQ ID NO:72.---

Art Unit: 1652

## Art of Record

11. The following are cited by the Examiner to complete the record, none of which affects the patentability of the allowed claims:

- a) GenBank Accession Number AAA87850. Bloom's syndrome protein. (November 25, 1995)
- b) GenBank Accession Number U39817. Human Bloom's syndrome protein (BLM) mRNA, complete cds. (November 25, 1995)
- c) Ellis *et al.* The Bloom's syndrome gene product is homologous to RecQ helicases. Cell (November 17, 1995) 83(4): 655-666.
- d) WO 97/17979 is Applicant's International application claiming priority to the U.S. application now USPN 5,824,501.
- e) USPN 6,399,378 (Ward et al.) teaches RECQL2 which is equivalent to SEQ ID NO:72 in the instant application.

#### Conclusion

12. Claims 12, 14-17, 19-20, and 86-93 are allowed.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Kathleen M Kerr whose telephone number is (571) 272-0931. The examiner can normally be reached on Monday through Friday, from 9:00am to 6pm.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Ponnathupura Achutamurthy can be reached on (571) 272-0928. The fax phone number for the organization where this application or proceeding is assigned is 703-872-9306.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

Kathleen M Kerr Primary Examiner Art Unit 1652

Kathle Ken